After halting development of the Phase III breast and lung cancer treatment iniparib in June because of lack of efficacy, Sanofi is pinning its near-term oncology hopes on fedratinib, a JAK2 inhibitor for myelofibrosis and the sole remaining oncology asset in Phase III.
Sanofi Oncology’s Transformation Rests On Fedratinib, At Least In The Near-Term
The JAK2 inhibitor for myelofibrosis is the company’s most advanced oncology candidate and will be an anchor for Sanofi as it looks to build a portfolio of next-generation cancer drugs after the late-stage failure of the PARP inhibitor iniparib.